Correlation Between Cardio Diagnostics and Xenon Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cardio Diagnostics and Xenon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cardio Diagnostics and Xenon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cardio Diagnostics Holdings and Xenon Pharmaceuticals, you can compare the effects of market volatilities on Cardio Diagnostics and Xenon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cardio Diagnostics with a short position of Xenon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cardio Diagnostics and Xenon Pharmaceuticals.

Diversification Opportunities for Cardio Diagnostics and Xenon Pharmaceuticals

0.31
  Correlation Coefficient

Weak diversification

The 3 months correlation between Cardio and Xenon is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Cardio Diagnostics Holdings and Xenon Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xenon Pharmaceuticals and Cardio Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cardio Diagnostics Holdings are associated (or correlated) with Xenon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xenon Pharmaceuticals has no effect on the direction of Cardio Diagnostics i.e., Cardio Diagnostics and Xenon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Cardio Diagnostics and Xenon Pharmaceuticals

Given the investment horizon of 90 days Cardio Diagnostics Holdings is expected to generate 4.3 times more return on investment than Xenon Pharmaceuticals. However, Cardio Diagnostics is 4.3 times more volatile than Xenon Pharmaceuticals. It trades about 0.05 of its potential returns per unit of risk. Xenon Pharmaceuticals is currently generating about 0.05 per unit of risk. If you would invest  29.00  in Cardio Diagnostics Holdings on September 5, 2024 and sell it today you would earn a total of  1.00  from holding Cardio Diagnostics Holdings or generate 3.45% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Cardio Diagnostics Holdings  vs.  Xenon Pharmaceuticals

 Performance 
       Timeline  
Cardio Diagnostics 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Cardio Diagnostics Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Cardio Diagnostics displayed solid returns over the last few months and may actually be approaching a breakup point.
Xenon Pharmaceuticals 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Xenon Pharmaceuticals are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting basic indicators, Xenon Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Cardio Diagnostics and Xenon Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cardio Diagnostics and Xenon Pharmaceuticals

The main advantage of trading using opposite Cardio Diagnostics and Xenon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cardio Diagnostics position performs unexpectedly, Xenon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenon Pharmaceuticals will offset losses from the drop in Xenon Pharmaceuticals' long position.
The idea behind Cardio Diagnostics Holdings and Xenon Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance